Lipid-induced insulin resistance in skeletal muscle: The chase for the culprit goes from total intramuscular fat to lipid intermediates, and finally to species of lipid intermediates

Nutrients

Volumn 8, Issue 8, 2016, Pages

  Kitessa, Soressa M ^a,b   Abeywardena, Mahinda Y ^a  

^a CSIRO   (Australia)

^b SOUTH AUSTRALIAN RESEARCH AND DEVELOPMENT INSTITUTE   (Australia)

Author keywords

Ceramides; DAG; Insulin resistance; Lipid intermediates; Skeletal muscle

Indexed keywords

CERAMIDE; DIACYLGLYCEROL; GLUCOSE TRANSPORTER 4; LIPID;

CELL MEMBRANE; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; LIPID DIET; LIPOTOXICITY; LOW FAT DIET; MUSCLE CELL; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SPHINGOLIPID METABOLISM; ABSORPTION; ADVERSE EFFECTS; ANIMAL; BIOLOGICAL MODEL; LIPID METABOLISM; METABOLISM; METABOLOMICS; PREDIABETIC STATE; PROCEDURES; TRENDS; WHITE ADIPOSE TISSUE;

ABSORPTION, PHYSIOLOGICAL; ADIPOSE TISSUE, WHITE; ANIMALS; CERAMIDES; DIET, HIGH-FAT; DIGLYCERIDES; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; METABOLOMICS; MODELS, BIOLOGICAL; MUSCLE, SKELETAL; PREDIABETIC STATE;

EID: 85015606073     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu8080466     Document Type: Review

References (74)

1. Pournaras, D.J.; le Roux, C.W. Type 2 diabetes: Multimodal treatment of a complex disease. Lancet 2015, 386, 936-937. [CrossRef]
2. Centre for Disease Control (CDC). Available online: http://www.cdc.gov/diabetes/basics/prediabetes.html (accessed on 11 August 2015).
3. Reaven, G.M. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37, 1595-1607. [CrossRef] [PubMed]
4. Samuel, V.T.; Shulman, G.I. Integrating mechanisms of insulin resistance: Common threads and missing links. Cell 2012, 148, 852-871. [CrossRef] [PubMed]
5. Samuel, V.T.; Petersen, K.-F.; Shulman, G.I. Lipid-Induced insulin resistance: Unravelling the mechanism. Lancet 2010, 375, 2267-2277. [CrossRef]
6. Warram, J.H.; Martin, B.C.; Krolewski, A.S.; Soeldner, J.S.; Khan, C.R. Slow glucose removal rate and hyperinsulinemia precede the development of Type II diabetes in the offspring of diabetic patients. Ann. Intern. Med. 1990, 113, 909-915. [CrossRef] [PubMed]
7. DeFronzo, R.A.; Tripathy, D. Skeletal muscle insulin resistance is primary defect in Type 2 Diabetes. Diabetes Car. 2009, 32 (Suppl. S2), S157-S163. [CrossRef] [PubMed]
8. Banting, F.G.; Best, C.H. The internal secretion of the pancreas. J. Lab. Clin. Med. 1922, 7, 251-266.
9. Freychet, P.; Roth, J.; Neville, D.M., Jr. Insulin receptors in the liver: specific binding of (125 I) insulin to the plasma membrane and its relation to insulin bioactivity. Proc. Natl. Acad. Sci. USA 1971, 68, 1833-1837. [CrossRef] [PubMed]
10. Myers, M.G.; White, M.F. Insulin receptor substrate-1 and proteins with SH2 domains. Diabetes 1993, 42, 643-650. [CrossRef] [PubMed]
11. Whitman, M.; Kaplan, D.R.; Schaffhausen, B.; Cantley, L.; Roberts, T.M. Association of phosphatidylinositol kinase activity with with polyoma middle-T component for transformation. Nature 1985, 315, 239-242. [CrossRef] [PubMed]
12. Allesi, D.R.; Deak, M.; Casamayor, A.; Caudwell, F.B.; Morrice, N.; Norman, D.G.; Gaffney, P.; Reese, C.B.; MacDougal, C.N.; Harbison, D. et al. 3-phosphoinositide dependent protein kinase-1 (PDK1): Structural and functional homology with the Drosophila DSTPK61 kinase. Curr. Biol. 1997, 7, 776-789. [CrossRef]
13. Franke, T.F.; Yang, S.I.; Chan, T.O.; Datta, K.; Kazlauskas, A.; Morrison, D.K.; Kaplan, D.R.; Tsichlis, P.N. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995, 81, 727-736. [CrossRef]
14. Inoue, M.; Kishimoto, A.; Takai, Y.; Nishizuka, Y. Guanosine 31:51-Monophosphate-dependent protein kinase from silkworm, properties of a catalytic fragment obtained by limited proteolysis. J. Biol. Chem. 1976, 251, 4476-4478. [PubMed]
15. Sano, H.; Kane, S.; Sano, E.; Minea, C.P.; Asara, J.M.; Lane, W.S.; Garner, C.W.; Lienhard, G.E. Insulin-Stimulated phosphorylation of a Rab GTPase activating protein regulates GLUT4 translocation. J. Biol. Chem. 2003, 278, 14599-14602. [CrossRef] [PubMed]
16. James, D.E.; Brown, R.; Navarro, J.; Pilch, P.F. Insulin regulatable tissues express a unique insulin-sensitive glucose transport protein. Nature 1988, 333, 183-185. [CrossRef] [PubMed]
17. Randle, P.J. Fuel selection in animals. Biochem. Soc. Trans. 1985, 14, 799-806. [CrossRef]
18. McFarlan, J.T.; Yoshida, Y.; Jain, S.S.; Han, X.X.; Snook, L.A.; Lally, J.; Smith, B.K.; Glatz, J.F.; Luiken, J.J.; Sayer, R.A. et al. In vivo, fatty acid translocase (CD36) critically regulates skeletal muscle fuel selection, exercise performance, and training-induced adaptation of fatty acid oxidation. J. Biol. Chem. 2012, 287, 23502-23516. [CrossRef] [PubMed]
19. Armstrong, D.T.; Steele, R.; Altszuker, N.; Dunn, A.; Bishop, J.S.; DeBodo, R.C. Regulation of plasma free fatty acid turnover. Am. J. Physiol. 1961, 201, 9-15. [PubMed]
20. Issekutz, B., Jr.; Bortz, W.M.; Miller, H.I.; Paul, P. Turnover rate of plasma FFA in humans and dogs. Metabolism 1967, 16, 1001-1009. [CrossRef]
21. Turcotte, L.P.; Kiens, B.; Richter, E.A. Saturation kinetics of palmitate uptake in perfused skeletal muscle. FEBS Lett. 1991, 279, 327-329. [CrossRef]
22. Kiens, B.; Kristiansen, S.; Jensen, P.; Richter, E.A.; Turcotte, L.P. Membrane associated fatty acid binding protein (FABPpm) in human skeletal muscle is increased by endurance training. Biochem. Biophys. Res. Commun. 1997, 231, 463-465. [CrossRef] [PubMed]
23. Glatz, J.F.C.; Luiken, J.J.F.P.; Bonen, A. Membrance fatty acid transporters as regulators of lipid metabolism: Implications for metabolic disease. Physiol. Rev. 2010, 90, 367-417. [CrossRef] [PubMed]
24. Kazantzis, M.; Stahl, A. Fatty acid transport proteins, implications in physiology and disease. Biochim. Biophys. Acta 2012, 1821, 852-857. [CrossRef] [PubMed]
25. Aitman, T.J.; Glazier, A.M.; Wallace, C.A.; Cooper, L.D.; Nortsworthy, J.K.; Wahid, F.N.; Al-Majali, K.M.; Trembling, P.M.; Mann, C.J.; Shoulders, C.C. et al. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat. Genet. 1999, 21, 76-83. [CrossRef] [PubMed]
26. Luiken, J.J.; Arumugam, Y.; Bell, R.C.; Calles-Escandon, J.; Tandon, N.N.; Glatz, J.F.; Bonen, A. Changes in fatty acid transport and transporters are related to the severity of insulin deficiency. Am. J. Physiol. Endocrinol. Metab. 2002, 283, E612-E621. [CrossRef] [PubMed]
27. Turner, N.; Cooney, G.J.; Kraegen, E.W.; Bruce, C.R. Fatty acid metabolism, energy expenditure and insulin resistance in muscle. J. Endocrinol. 2014, 220, T61-T79. [CrossRef] [PubMed]
28. Kampmann, U.; Christensen, B.; Nielsen, T.S.; Pedersen, S.B.; Ørskov, L.; Lund, S.; Møller, N.; Jessen, N. GLUT4 and UBC9 protein expression is reduced in muscle from type 2 diabetic patients with severe insulin resistance. PLoS ONE 2011, 6, e27854. [CrossRef] [PubMed]
29. Funai, K.; Semenkovich, C.F. Skeletal muscle lipid flux: Running water carries no poison. Am. J. Physiol. Endocrinol. Metab. 2011, 301, E245-E251. [CrossRef] [PubMed]
30. Zamora, M.; Josep, A.; Villena, J.A. Targeting mitochondrial biogenesis to treat insulin resistance. Curr. Pharm. Des. 2014, 20, 5527-5557. [CrossRef] [PubMed]
31. Valero, T. Mitochondrial biogenesis: Pharmacological approaches. Curr. Pharm. Des. 2014, 20, 5507-5509. [CrossRef] [PubMed]
32. Besseiche, A.; Riveline, J.-P.; Gautier, J.-F.; Breant, B.; Blondeau, B. Metabolic roles of PGC-α and its implications for type 2 diabetes. Diabetes Metab. 2015, 41, 347-357. [CrossRef] [PubMed]
33. Liang, H.; Ward, W.F. PGC-1α: A key regulator of energy metabolism. Adv. Physiol. Educ. 2006, 30, 145-151. [CrossRef] [PubMed]
34. Hoeks, J.; Schrauwen, P. Muscle mitochondria and insulin resistance: A human perspective. Trends Endocrinol. Metab. 2012, 23, 444-450. [CrossRef] [PubMed]
35. Jo, J.; Gavrilova, O.; Pack, S.; Jou, W.; Mullen, S.; Summer, A.E.; Cushman, S.W.; Periwal, V. Hypertrophy and/or hyperplasia: Dynamics of adipose tissue growth. PLoS Comput. Biol. 2009, 5, e1000324. [CrossRef] [PubMed]
36. Goodpaster, B.H.; He, J.; Watkins, S.; Kelley, D.E. Skeletal muscle lipid content and insulin resistance: Evidence for a paradox in endurance-trained athletes. J. Clin. Endocrinol. Metab. 2001, 86, 5755-5761. [CrossRef] [PubMed]
37. Dubé, J.J.; Amati, F.; Stefanovic-Racic, M.; Toledo, F.G.S.; Sauers, S.E.; Goodpaster, B.H. Exercise-Induced alterations in intramyocellular lipids and insulin resistance: The athlete’s paradox revisited. Am. J. Physiol. Endocrinol. Metab. 2008, 294, E882-E888. [CrossRef] [PubMed]
38. Unger, R.H. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: Genetic and clinical implications. Diabetes 1995, 44, 863-870. [CrossRef] [PubMed]
39. Amti, F. Revisiting the diacylglycerol-induced insulin resistance hypothesis. Obes. Rev. 2012, 13 (Suppl. S2), 40-50. [CrossRef] [PubMed]
40. Erion, D.M.; Shulman, G.I. Diacylglycerol-Mediated insulin resistance. Nat. Med. 2010, 16, 400-402. [CrossRef] [PubMed]
41. Yu, C.; Chen, Y.; Cline, G.W.; Zhang, D.; Zhong, H.; Wang, Y.; Bergeron, R.; Kim, Y.K.; Cushman, S.W.; Cooney, G.J. et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 2002, 277, 50230-50236. [CrossRef] [PubMed]
42. Griffin, M.E.; Marcucci, M.J.; Cline, G.W.; Bell, K.; Barucci, N.; Lee, D.; Goodyear, L.J.; Kraegen, E.W.; White, M.F.; Shulman, G.I. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C θ and alterations in insulin signalling cascade. Diabetes 1999, 48, 1270-1274. [CrossRef] [PubMed]
43. Itani, S.I.; Ruderman, N.B.; Schmieder, F.; Boden, G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkB-α. Diabetes 2002, 51, 2005-2011. [CrossRef] [PubMed]
44. Li, M.; Veinberg, S.G.; Bezy, O.; O’Neill, B.T.; Kahn, C.R. Role of PKCδ in insulin sensitivity and skeletal muscle metabolism. Diabetes 2015, 64, 4023-4032. [CrossRef] [PubMed]
45. Lam, Y.Y.; Hatzinikolas, G.; Weir, J.M.; Janovska, A.; McAinch, A.J.; Game, P.; Meikle, P.J.; Wittert, G.A. Insulin-Stimulated glucose uptake and pathways regulating energy metabolism in skeletal muscle cells: The effects of subcutaneous and visceral fat, and long-chain saturated, n-3 and n-6 polyunsaturated fatty acids. Biochim. Biophy. Acta 2011, 1811, 468-475. [CrossRef] [PubMed]
46. Selathurai, A.; Kowalski, G.M.; Burch, M.L.; Sepulveda, P.; Risis, S.; Lee-Young, R.S.; Lamon, S.; Meikle, P.J.; Genders, A.J.; McGee, S.L. et al. The CDP-Ethanolamine pathway regulates skeletal muscle diacylglycerol content and mitochondrial biogenesis without altering insulin sensitivity. Cell Metab. 2015, 21, 718-730. [CrossRef] [PubMed]
47. Szendroedi, J.; Yoshimura, T.; Phielix, E.; Koliaki, C.; Marucci, M.; Zhang, D.; Jelenik, T.; Muller, J.; Herder, C.; Nowotny, P. et al. Role of diacylglycerol activation of PKCθ in lipid-induced muscle insulin resistance in humans. Proc. Natl. Acad. Sci. USA 2014, 111, 9597-9602. [CrossRef] [PubMed]
48. Ritter, O.; Jelenik, T.; Roden, M. Lipid-Induced muscle insulin resistance: different fat, different pathways. J. Mol. Med. 2015, 93, 831-843. [CrossRef] [PubMed]
49. Takai, Y.; Kishimoto, A.; Kikkawa, U.; Mori, T.; Nishizuka, Y. Unsaturated diacylglycerol as a possible messenger for the activation of calcium-activated, phospholipid-dependent protein kinase system. Biochem. Biophys. Res. Commun. 1979, 91, 1218-1224. [CrossRef]
50. Nishizuka, Y. Discovery and prospect of protein kinase C research: Epilogue. J. Biochem. 2003, 133, 155-158. [CrossRef] [PubMed]
51. Turner, N.; Kowalski, G.M.; Leslie, S.J.; Risis, S.; Yang, C.; Lee-Young, R.S.; Babb, J.R.; Meikle, P.J.; Lancaster, G.I.; Hentridge, D.C. et al. Distinct patterns of tissue specific lipid accumulation during the induction of insulin resistance in mice by high-fat feeding. Diabetologia 2013, 56, 1638-1648. [CrossRef] [PubMed]
52. Yusuf, A.H.; Lina, M.O. Principles of bioactive lipid signalling: Lessons from sphingolipids. Nat. Rev. Mol. Cell Biol. 2008, 9, 139-150.
53. Lee, J.S.; Pinnamaneni, S.K.; Eo, S.J.; Cho, I.H.; Pyo, J.H.; Kim, C.K.; Sinclair, A.J.; Febrraio, M.A.; Watt, M.J. Saturated, but not n-6 polyunsaturated, fatty acids induce insulin resistance: Role of intramuscular accumulation of lipid metabolites. J. Appl. Physiol. 2006, 100, 1467-1474. [CrossRef] [PubMed]
54. Newson, S.A.; Everett, A.C.; Park, S.; Van Pelt, D.W.; Hinko, A.; Horowitz, J.F. Lipid mixtures containing a very high proportion of saturated fatty acids only modestly impair insulin signalling in cultured muscle cells. PLoS ONE 2015, 10, e0120871. [CrossRef]
55. Merrill, A.H., Jr. Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem. Rev. 2011, 111, 6387-6422. [CrossRef] [PubMed]
56. Holland, W.L.; Brozinick, J.T.; Wang, L.P.; Hawkins, E.D.; Sargent, K.M.; Liu, Y.Q.; Narra, K.; Hoehn, K.L.; Knotts, T.A.; Siesky, A. et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 2007, 5, 167-179. [CrossRef] [PubMed]
57. Chavez, J.A.; Siddique, M.M.; Wang, S.T.; Ching, J.H.; Shayman, J.A.; Summers, S.A. Ceramides and glucosylceramides are independent antagonists of insulin signaling. J. Biol. Chem. 2014, 289, 723-734. [CrossRef] [PubMed]
58. Holland, W.L.; Bikman, B.T.; Wang, L.P.; Yuguang, G.; Sargent, K.M.; Bulchand, S.; Knotts, T.A.; Shui, G.H.; Clegg, D.J.; Wenk, M.R. et al. Lipid-Induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J. Clin. Investig. 2011, 121, 1858-1870. [CrossRef] [PubMed]
59. Holand, W.L.; Summers, S.A. Sphingolipids, insulin resistance, and metabolic disease: New insights from in vivo manipulation of sphingolipid metabolism. Endocr. Rev. 2008, 29, 381-402. [CrossRef] [PubMed]
60. Summers, S.A. Sphingolipids and insulin resistance: The five Ws. Curr. Opin. Lipidol. 2010, 21, 128-135. [CrossRef] [PubMed]
61. Chavez, J.A.; Summers, S.A. A ceramide-centric view of insulin resistance. Cell Metab. 2012, 15, 585-594. [CrossRef] [PubMed]
62. Chaurasia, B.; Summers, S.A. Ceramides-Lipotoxic inducers of metabolic disorders. Trends Endocrinol. Metab. 2015, 26, 538-550. [CrossRef] [PubMed]
63. Siddique, M.M.; Li, Y.; Chaurasia, B.; Kaddai, V.A.; Summers, S.A. Dihydroceramides: From bit players to lead actors. J. Biol. Chem. 2015, 290, 15371-15379. [CrossRef] [PubMed]
64. Shimabukuro, M.; Higa, M.; Zhou, Y.T.; Wang, M.Y.; Newgard, C.B.; Unger, R.H. Lipoapoptosis in beta-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. J. Biol. Chem. 1998, 273, 32487-32490. [CrossRef] [PubMed]
65. Watson, M.L.; Coghlan, M.; Hundal, H.S. Modulating serine palmitoyl transferase (SPT) expression and activity unveils a crucial role in lipid-induced insulin resistance in rat skeletal muscle cells. Biochem. J. 2009, 417, 791-801. [CrossRef] [PubMed]
66. Skovbro, M.; Baranowski, M.; Skov-Jensen, C.; Flint, A.; Dela, F.; Gorski, J.; Helge, J.W. Human skeletal muscle ceramide content is not a major factor in muscle insulin sensitivity. Diabetologia 2008, 51, 1253-1260. [CrossRef] [PubMed]
67. Helge, J.W.; Stalknectt, B.; Drachmann, T.; Hellgren, L.I.; Jimenez-Jimenez, R.; Andersen, J.L.; Richelsen, B.; Bruun, J.M. Improved glucose tolerance after intensive life style intervention occurs without change in muscle ceramide or triacylglycerol in morbidly obese subjects. Acta Physiol. (Oxf.) 2011, 201, 357-364. [CrossRef] [PubMed]
68. Dubé, J.J.; Amati, F.; Stefanovic-Racic, M.; Rossi, A.; Coen, P.; Goodpaster, B.H. Effects of weight loss and exercise on insulin resistance, and on intramyocellular triacylglycerol, diacylglycerol and ceramide. Diabetologia 2011, 54, 1147-1156. [CrossRef] [PubMed]
69. Raicur, S.; Wang, T.; Chan, P.W.; Li, Y.; Ching, J.; Chaurasia, B.; Dogra, S.; Ohman, M.K.; Takeda, K.; Sugii, S. et al. CerS2 haploinsufficiency inhibits β-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell Metab. 2014, 20, 687-695. [CrossRef] [PubMed]
70. Turpin, S.M.; Nicholls, H.T.; Willmes, D.M.; Mourier, A.; Brodesser, S.; Wunderlich, C.M.; Maur, J.; Xu, E.; Hammerschmidt, P.; Bronneke, H.S. et al. Obesity-induced Cers6-dependent c16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab. 2014, 20, 678-686. [CrossRef] [PubMed]
71. Bergman, B.C.; Brozinick, J.T.; Straus, A.; Bacon, S.; Kerege, A.; Bui, H.H.; Sanders, P.; Siddall, P.; Wei, T.; Thomas, M.K. et al. Muscle sphingolipids during rest and exercise: C18:0 signature for insulin resistance. Diabetologia 2016, 59, 785-798. [CrossRef] [PubMed]
72. De La Maza, M.P.; Rodriguez, J.M.; Hirsch, S.; Leiva, L.; Barrera, G.; Bunout, D. Skeletal muscle ceramide species in men with abdominal obesity. J. Nutr. Health Aging 2015, 19, 389-396. [CrossRef] [PubMed]
73. Kasumov, T.; Solomon, T.P.J.; Hwang, K.; Hunag, H.; Haus, J.M.; Zhang, R.; Kirwan, J.P. Improved insulin sensitivity after exercise training is linked to reduced plasma C14:0 ceramide in obesity and Type 2 Diabetes. Obesity 2015, 23, 1414-1421. [CrossRef] [PubMed]
74. Caricilli, A.M.; Saad, M.J.A. The role of gut microbiota on insulin resistance. Nutrients 2013, 5, 829-851. [CrossRef] [PubMed]